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16Introduction
In the development of imaging agents for neurological studies,
most of the steps in the biosynthesis, storage, transport, release,
receptor binding, reuptake, and catabolism of several major neu-
rotransmitters have now been targeted.1 For the monoamine
neurotransmitters, such as dopamine and serotonin, these
efforts have been quite successful and have provided a rich
arsenal of radiolabeled compounds useful for examining the
changes in biochemistry occurring in a wide variety of neurologi-
cal and psychiatric disorders.
A central and common step in neurotransmission is the storage
and release of neurotransmitters via synaptic storage vesicles. The
movement of neurotransmitter molecules (either newly synthe-
sized or being recycled via the neuronal membrane transporters)
into the lumen of the storage vesicles is accomplished by an active
transport system via specific proteins termed the vesicular
transporters.2 Two of these transporters have been successfully
targeted for in vivo radiotracer development: the vesicular
monoamine transporter type 2 (VMAT2) and the vesicular acet-
ylcholine transporter (VAChT).3 Although there are obligatory
transporters for other neurotransmitter systems (e.g., vesicular
glutamate transporter (VGLUT) for glutamate and vesicular
GABA transporter (VGAT) for gamma-amino butyric acid (GABA))
no successful radiotracers have to date been developed for
those amino acid vesicular transporters.
Radioligands for the vesicular monoamine
transporters
The VMAT2 is a relatively unspecific transporter, as it functions to
move a wide variety of amines into the vesicle lumen, including
dopamine, serotonin, norepinephrine, histamine, and a number
of structurally related molecules.4,5 The VMAT2 (SLC18A1) is
located primarily in the brain, although it is also found in nerves
and exocrine cells in the periphery; the structurally related vesicu-
lar monoamine transporter type 1 (SLC18A2, with 40% sequence
homology) is peripherally located with high concentrations in
the adrenals. Vesicular transporters for the monoamines are sepa-
rate from and bear no structural homology to the dopamine,J. Label Compd. Radiopharm 2013, 56 167–171serotonin, and norepinephrine neuronal membrane monoamine
transporters. The VMAT2 transports positively charged amine
substrates into the lumen with concomitant extrusion of two
protons: the protons are generated within vesicles by the action
of a separate membrane-bound adenosine triphosphatase. The
amino acid sequencing of the VMAT2 has been accomplished,
and the models of tertiary structure suggest a 12-transmembrane
domain configuration with both the amino and carboxyl terminal
ends within the cytoplasm, and a single large intraluminal loop.
As the VMAT2 is not specific and is found in all monoaminergic
neurons, the distinction of a neuron as being dopaminergic, sero-
tonergic, or noradrenergic is determined by the combination of
VMAT2 with the neurotransmitter-specific biosynthetic enzymes
and corresponding neuronal membrane transporter. The VMAT2
is likely a necessary protein for survival in mammals, as homozy-
gous knockout of the transporter in mice is lethal.
The successful radiotracers for in vivo imaging of the VMAT2 are
all derived from the structure of tetrabenazine (TBZ: 3-isobutyl-
9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-pyrido[2,1-a]isoquino-
lin-2-one, Figure 1), a drug developed in the mid-20th century6 and
still in clinical use today (XenazineR). TBZ has a high affinity for the
VMAT2 (Kd values of 1–2nM) with no appreciable affinity for any
other receptor or transporter binding sites. The initial synthesis of
carbon-11-labeled TBZ7 involved the introduction of the carbon-11
into the 9-methoxy group, with the needed phenolic precursor
prepared by a low yield and nonspecific demethylation using
broron tribromide. Identification and assignment of the 9- versusCopyright © 2013 John Wiley & Sons, Ltd.
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16810-demethylation products were carried out by comparisons of pro-
ton and carbon-13 NMR spectra, and ultimately by total synthesis of
the 9-desmethyl compound by an independent route. Alkylation of
the 9-desmethylTBZ precursor with [11C]methyl iodide8 yielded a
radiotracer that, as an isotopic substitution of the clinical drug, could
be rapidly introduced into clinical studies as there were no safety
questions; the pharmacology andmetabolism of the drug were very
well known.9,10 The demonstration of the utility of the radiotracer toFigure 1. Positron emission tomography radioligands for the vesicular monoamine
www.jlcr.org Copyright © 2013 John Wiley & Sonsimage the VMAT2 in the basal ganglia of the human,11 with
pharmacokinetics appropriate for modeling to extract estimates of
important binding parameters, quickly followed.
From the initial synthesis of [11C]TBZ, development of VMAT2
imaging agents took a rapidly improving pathway. The recognition
that the chemical species present in the bloodstream very rapidly
after TBZ administration was in fact a metabolite, 2-dihydrotetra-
benazine (DTBZ: 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-
hexahydrobenzo[a]quinolizin-2-ol, Figure 1), coupled with the
demonstration that the metabolite also has a high affinity for the
VMAT2, suggested that the brain uptake and localization of radio-
activity following [11C]TBZ administration also likely represented
predominantly the radiolabeled metabolite. This realization led to
the deliberate syntheses and evaluation in vivo of a- and b-DTBZ,
the two isomers resulting from the nonstereoselective chemical
reduction of the 2-ketone group of TBZ.8,12 The use of the
higher-affinity isomer, a-DTBZ, was then quickly implemented as
the preferred VMAT2 radiotracer and required only the synthesis
of the needed precursor a-9-O-desmethylDTBZ; this was prepared
in an improved yield and selectivity using demethylation with
sodium hydride/N-methylaniline/hexamethylphosphoramide as
reagent. The phenolic precursor was then alkylated with [11C]
methyl iodide to yield the desired a-[11C]DTBZ13: the free second-
ary alcohol is unreactive under the mild basic conditions used for
the methylation.
The next insight into the improvement of VMAT2 radiotracers
resulted from studies using chiral column chromatography to
separate the isomers of DTBZ.14 TBZ, the clinically used drug, was
and still is today utilized as a racemic mixture of stereoisomers:
with two chiral carbon centers, there would be four
possible stereoisomers, and the drug composition was unknown.
Reduction of the ketone of TBZ produces an additional chiral
carbon, resulting in eight possible stereoisomers for DTBZ. The
isomers at the 2-position (termed a- and b-) are readily separated
by simple column chromatography, and subsequent chiral HPLC
analysis of pure a-DTBZ indicated the presence of only two
stereoisomers. Careful chromatography yielded pure samples
of both, from which it could be determined that the (+)-isomer
(nomenclature reflecting the direction of rotation of polarized
light) bound with a high affinity (approximately 1nM), with the
()-isomer showed negligible binding (>4000 nM).13 Thetransporter type 2.
, Ltd. J. Label Compd. Radiopharm 2013, 56 167–171
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16absolute stereochemistry of these isomers was next determined
by X-ray crystallography of the inactive ()-isomer, allowing an
assignment of (+)-a-DTBZ as having the (2R,3R,11bR) stereo-
chemistry.14 This was the first definition of stereochemistry of DTBZ
molecules: in subsequent years, all of the possible stereoisomers of
DTBZ have been independently synthesized and the absolute
stereochemistry and affinity for VMAT2 determined for each
one.15–17 As it turns out, (+)-a-DTBZ ((2R,3R,11bR) stereochemistry)
is the highest affinity VMAT2 ligand amongst the eight isomers.
These results also suggest the [11C]TBZ previously prepared, as
well as clinically used TBZ, are a mixture of the 3R,11bR and
3S,11bS enantiomers.
The syntheses of both (+)- and ()-a-[11C]DTBZ were next
accomplished by the preparation of the necessary (+)- and ()-
a-9-O-desmethylDTBZ precursors, which could then be readily
alkylated with no-carrier-added [11C]methyl iodide.18 Syntheses
of the two chirally resolved desmethyl precursors were originally
carried out using selective O-demethylation of racemic a-DTBZ
and tedious isolation of the desired mono-demethylated pro-
duct, followed by preparative chiral chromatographic separation,
and isolation of the (+) and ()-a-9-O-desmethylDTBZ isomers.14
In more recent years, there have been a number of new syn-
thetic approaches to the synthesis of TBZ and DTBZ, which allow
simpler preparations of this class of molecules.19–21
The (+)-a-[11C]DTBZ (Figure 1) has become the preferred in vivo
positron emission tomography (PET) radioligand for studies of the
VMAT2 in normal and diseased brain: the synthesis of the radioli-
gand has now been reproduced bymultiple research groups using
solution chemistry, loop chemistry, and solid-phase-supported
chemical synthesis techniques. The dynamic PET data obtained
from the human PET studies can be readily applied to pharmacoki-
netic models, or utilized in graphical analyses, to yield estimates of
binding potential for this radiopharmaceutical.22 Studies of the
VMAT2 using [11C]DTBZ have now been reported in Parkinson’s
disease, Alzheimer’s disease, Huntington’s disease, schizophrenia,
drug abuse, bipolar disorder, Tourettes syndrome, and other neu-
rological and psychiatric disorders.23,24
The carbon-11-labeled radiopharmaceutical has proven itself a
very useful compound for medical research studies. Transition of
any carbon-11 compound to truly widespread clinical applica-
tions has always presented problems; this has usually been
addressed by the development of analogous fluorine-18-labeled
radiotracers. In the VMAT2 area, this has also been successfully
accomplished. Several different approaches were taken to
developing fluorine-18-labeled derivatives of (2R,3R,11bR)DTBZ
(Figure 1), leading to potential radioligands with fluorine-18
containing substituents at the 9-position (fluoroalkyl ethers25,26)
or at the 2-position (alkyl substitutents on the 2-carbon or
ethers of the hydroxyl group27). The most thoroughly studied
compound has been 9-O-(3-[18F]fluoropropyl)-(+)-a-DTBZ
(termed FP-DTBZ, or AV-133; 9-methoxy-10-(3-[18F]fluoropropyl)-3-
(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-
ol), prepared by [18F]fluoride ion displacement of a suitably
positioned tosylate or mesylate leaving group.26,28 This simple
substitution of a fluoropropyl group for the methoxy group of
(+)-a-DTBZ actually resulted in a derivative with a higher
in vitro binding affinity (Ki = 0.1 nM).
29 In vivo studies of the
fluorinated derivative in rodents26 and monkeys30 demonstrated
excellent specific localization in monoaminergic neurons of the
brain, suitable pharmacokinetics, and no significant interfering
metabolites. As a new chemical entity, it of course required
completion of dosimetry31 and toxicology studies prior toCopyrigJ. Label Compd. Radiopharm 2013, 56 167–171submission for regulatory approval for human studies. Of the
numerous fluorinated DTBZ derivatives, most of which exhibit
high affinity for the VMAT2, (+)-a-[18F]FP-DTBZ (AV-133)
remains the only radiotracer that has been applied to human
clinical studies of the VMAT2 including studies in Parkinson’s
disease.32–34
Radioligands for the vesicular acetylcholine
transporter
The VAChT (SLC18A3) is responsible for the movement of newly
synthesized acetylcholine from the cytosol to the vesicular
lumen.3 In contrast to the VMAT2, there are no subtypes, and
the VAChT is generally not found in other neuronal types than
cholinergic neurons. The VAChT shares a gene locus with the
acetylcholine-synthesizing enzyme choline acetyltransferase, in
what has been termed the cholinergic locus. The VAChT shares
some (approximately 40%) sequence homology with the vesicu-
lar monoamine transporter type 1 and VMAT2 and has been
proposed to have a similar 12-transmembrane domain tertiary
structure with cytoplasmic N- and C-terminal domains and a
single large intra-vesicular loop. Similar to the VMAT2, the
stoichiometry of exchange of acetylcholine for protons is also
suggested to be 1 : 2. The structure and function of the VAChT
remains, however, less fully investigated than the related VMAT2.
As with the VMAT2, the VAChT is required for survival, as homo-
zygous VAChT knockout mice die shortly after birth.35
From a radiotracer development point, the VAChT has proved
much more difficult to approach; there are no clinically approved
drugs that bind to this transporter, and in fact, inhibition of
the VAChT produces severe pharmacological reactions leading
to death. The development of radiotracers, therefore, has
depended on radiolabeling of xenobiotics, primarily based on a
compound known as vesamicol (trans-2-(4-phenyl-1-piperidyl)
cyclohexan-1-ol, Figure 2). Originally reported in 1983, vesamicol
has two chiral centers: high affinity for the VAChT (Ki = 1–2 nM) is
observed only for the ()-isomer (absolute configuration 1R,2R)
and 25-fold lower affinity for the (+)-isomer.36 A large number
of derivatives of vesamicol have been synthesized and many
show high to extremely high (subnanomolar) affinity.36 Unfortu-
nately, vesamicol also exhibits high binding to one or both of the
sigma receptor binding sites,37,38 and thus, early studies of radi-
olabeled vesamicol and simple derivatives of that structure39 did
not find successful applications for in vivo imaging.
Despite the challenges in working with the VAChT, a signifi-
cant number of entirely new compounds were synthesized and
many radiolabeled in the search for a useful PET radioligand
for human imaging. These efforts have yielded vesamicol deriva-
tives with added aromatic or morpholino rings, additional ring
nitrogens, spirocyclic structures, or combinations of these struc-
tural changes in the attempt to develop radioligands with high
affinity for the VAChT and selective against other binding sites,
particularly sigma receptors.
Benzovesamicols and related as vesicular acetylcholine
transporter ligands
(-)-Benzovesamicols ((-)-3-(4-phenyl-piperidin-1-yl)-1,2,3,4-tetra-
hydro-naphthalen-2-ol, Figure 2) have a benzene ring fused to
the structure of vesamicol and in general exhibit high affinity
for the VAChT. That additional aryl ring offered several positions
for attachment of radiohalogens or substituents containingwww.jlcr.orght © 2013 John Wiley & Sons, Ltd.
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Figure 2. Positron emission tomography radioligands for the vesicular acetylcholine
transporter.
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170carbon-11 or fluorine-18. Of the possible derivatives, it was
determined that substituents at the 5-position were not detri-
mental and sometimes increased binding affinity, but more
importantly, the 5-substituted ()-benzovesamicols showed
low or negligible affinity for sigma receptors or any other bind-
ing sites. This led to the synthesis of the earliest successful radi-
oligand ()-5-[123I]iodobenzovesamicol, introduced into human
studies in 199440 and in still in use at the current time.41
The search for a suitable PET radioligand for the VAChT based
on the ()-benzovesamicol structure42 was initiated simulta-
neously with the development of a single-photon emission
computed tomography radiopharmaceutical but has taken
much longer to reach conclusion. Numerous carbon-11-labeled
and fluorine-18-labeled 5-substituted (-)-benzovesamicols were
synthesized and evaluated in animals,42–45 as well as derivatives
labeled at the opposite end of the molecule by the insertion of a
ketone group into the phenylpiperidine structure.46 Many of
these derivatives showed very good brain uptake and specific
localization in cholinergic structures, and several exhibit accep-
table selectivity over binding to sigma receptor sites. Of the
numerous compounds tested in animals, the derivative ()-5-
(2-[18F]fluoroethoxy)benzovesamicol (Ki = 1 nM) was selected
for further development into a radiopharmaceutical for human
applications.45 This radiopharmaceutical is prepared by no-
carrier-added [18F]fluoride ion displacement of the tosylate
precursor; because of the known toxicity of VAChT inhibitors,
this synthesis requires not only strict quality control measures to ver-
ify both the high specific activity needed (typically>222TBq/mmol)
but also the complete removal of the precursor and any side
products (e.g., hydroxyl derivative). As this was a new chemical
entity, and given the known toxicity of vesamicol derivatives,
extensive preclinical animal studies including toxicology/www.jlcr.org Copyright © 2013 John Wiley & Sonspathology and dosimetry were completed before achieving
approval for human studies. This approval has only recently
been granted, but preliminary human imaging studies of the
VAChT in the brain have been highly promising (K Frey et al.,
personal communication).
In a related attempt to modify the structure of ()-vesamicol,
Sorger et al.47 reported the synthesis of derivatives with substi-
tuted morpholino rings fused onto the ()-vesamicol structure
(phenylpiperidinyl-octahydro-benzo[1,4]oxazines). This series of
compounds yielded derivatives with good affinity for the VAChT
and selectivity for the VAChT over the sigma receptor binding sites.Trozamicols and related vesicular acetylcholine transporter
radioligands
An alternative approach to VAChT radioligands was taken in the
design and synthesis of analogs of ()-vesamicol, which were
termed trozamicols (Figure 2). These are slightly different struc-
tures that still incorporate the basic structural features of vesami-
col but contain an additional nitrogen in the hydroxypiperidine
ring portion.48 This provides an additional readily accessible
position for introduction of radiolabeled groups such as a [18F]
fluorobenzyl or [18F]fluorobenzoyl moiety; an example is [18F]
fluorobenzyltrozamicol (Ki = 14 nM, Figure 2). An alternative is
the attachment of an N-substituted spirocyclic piperidine ring
in a series of what are termed spiro-trozamicols.49 Numerous of
these substituted trozamicol and spiro-trozamicols compounds
have now been synthesized, and several have been demon-
strated to be useful for in vivo imaging of the VAChT in rodent
and primate brain. To date, none of the trozamicol derivatives
have been successfully taken to human studies.Conclusions
The development of in vivo imaging radioligands for the two
vesicular transporters, VMAT2 and VAChT, is providing interesting
contrasts. The development of VMAT2 radioligands was based on
a known clinically used drug (TBZ), and that allowed rapid imple-
mentation into human studies of first the isotopically labeled drug
itself, followed in a reasonable time by radiolabeled derivatives
meant to improve pharmacokinetics andmetabolism or to provide
wider availability (fluorine-18 radiolabeling). The development of
VAChT radioligands depended on the modifications of a xenobio-
tic, vesamicol, which was a compound with known high toxicity
and poor selectivity for the transporter site. Although a consider-
able number of analogs and derivatives of vesamicol have been
synthesized and radiolabeled, progress towards human studies
was impeded by the demands for full toxicological testing, and
after two decades of work, only a single compound ([18F]fluor-
oethoxybenzovesamicol) has to date reached the endpoint of
evaluation in human PET studies.Acknowledgement
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